DPYD

DPYD Sequencing Identifies More Clinically Relevant Variants as Compared to Targeted Genotyping

Déficit en DPYD — séquençage exhaustif vs génotypage ciblé pour identifier les patients à risque de toxicité aux fluoropyrimidines

Importance of and Strategies for Implementing DPYD Testing to Prevent Severe Fluoropyrimidine Chemotherapy Toxicity in Health Care Systems

Implémentation du test DPYD avant fluoropyrimidines — recommandations FDA 2025 et stratégies institutionnelles de déploiement

Integrating Somatic and Germline Pharmacogenomics for Therapeutic Decisions in Precision Oncology.

Pharmacogénomique en oncologie de précision — intégration somatique + germinale chez 10 302 patients cancéreux (TCGA)

Importance of and Strategies for Implementing DPYD Testing to Prevent Severe Fluoropyrimidine Chemotherapy Toxicity

Toxicité sévère aux fluoropyrimidines (5-FU, capécitabine, tégafur) — neutropénie, mucite sévère, décès

DPYD c.85 T > C, DPYD c.496 A>G, and DPYD c.2194 G>A and severe toxicity to fluoropyrimidines in PREPARE and Alpe-DPD trials. An original study and meta-analysis.

Toxicité sévère aux fluoropyrimidines

The variant c.2766+3A>T in DPYD leads to exon 21 skipping and is associated with DPD deficiency and severe fluoropyrimidine toxicity.

Déficit en dihydropyrimidine déshydrogénase et toxicité des fluoropyrimidines

DPYD polymorphisms in Native populations from the Brazilian Amazon: the absence of the variants in currently recommended clinical genotyping panels

Toxicité des fluoropyrimidines — variantes DPYD en populations autochtones

DPYD and UGT1A1 Genotype-Based Dosing for Fluoropyrimidines and Irinotecan Chemotherapy: Variant-Specific Impact on Treatment Intensity and Toxicity.

Toxicité aux fluoropyrimidines et à l'irinotécan

Considerations for the clinical implementation of DPYD and UGT1A1-guided chemotherapy

DPYD et UGT1A1 — implémentation clinique du test pharmacogénomique guidant la chimiothérapie par fluoropyrimidines et irinotécan

Clinical response to capecitabine in a DPYD*2A homozygous patient: Case report and therapeutic guidance.

Déficit complet en DPD (DPYD2A homozygote) — capécitabine ultra-faible dose

Cost-effectiveness of DPYD genotyping prior to fluoropyrimidine-based treatment for colorectal cancer in Wales.

Cancer colorectal — toxicité fluoropyrimidines

Dihydropyrimidine dehydrogenase (DPYD) genetic testing and treatment with 5-fluoropyrimidines in cancer patients

Cancer — prévention de la toxicité aux 5-fluoropyrimidines

Characterization of DPYD pharmacogenetic variation in Mexican patients with gastrointestinal malignancies.

Toxicité aux fluoropyrimidines dans les cancers digestifs

Prevalence and clinical impact of the uncommon DPYD c.257C>T (Pro86Leu) variant in a multiethnic cohort receiving fluoropyrimidine therapy.

Toxicité sévère aux fluoropyrimidines

DPYD Genotyping of Patients with Fluoropyrimidine Treatment: Results of Protocol Implementation and Outcomes of Patients Carrying Unusual DPYD Variants

Toxicité des fluoropyrimidines